Stay updated on Prohibitin Peptide 1 in Metastatic Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Prohibitin Peptide 1 in Metastatic Prostate Cancer Clinical Trial page.

Latest updates to the Prohibitin Peptide 1 in Metastatic Prostate Cancer Clinical Trial page
- Check7 days agoChange DetectedAdded related topics: Prostate cancer and MedlinePlus Genetics appear as related topics on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check14 days agoChange DetectedRevision: v3.4.2 was added. The notice about government funding lapse and Revision: v3.4.1 were removed.SummaryDifference0.5%

- Check21 days agoChange DetectedA site-wide notice about a lapse in government funding and potential information delays was added. The page revision tag was updated from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check28 days agoChange DetectedAdded: Show glossary, Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0. Removed: Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.2%

- Check42 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4, a minor technical update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check56 days agoChange DetectedAdded a Texas location under Locations and updated the revision to v3.3.3. Removed footer/related entries for HHS Vulnerability Disclosure, MedlinePlus Genetics, and Texas Locations.SummaryDifference0.4%

Stay in the know with updates to Prohibitin Peptide 1 in Metastatic Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Prohibitin Peptide 1 in Metastatic Prostate Cancer Clinical Trial page.